Literature DB >> 7980579

Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells.

A Hori1, S Ikeyama, K Sudo.   

Abstract

The effects of TNP-470 on DNA synthesis and the expression of c-myc and cyclin D1 mRNAs were investigated in human umbilical vein endothelial (HUVE) cells synchronized by serum depletion and stimulated with bFGF and serum. DNA synthesis occurring 16 h after stimulation was inhibited when TNP-470 was present from 2 to 6 h after stimulation. C-myc mRNA expression occurring 2 h after stimulation was not inhibited by the addition of TNP-470. Cyclin D1 mRNA expression occurring 6 h after stimulation was suppressed in the presence of TNP-470 from 2 to 6 h after stimulation. On the other hand, cyclin D1 expression was not suppressed in the TNP-470-insensitive human tumor cell line WiDr. These results suggest that the inhibition of HUVE cells by TNP-470 is due to the suppression of cyclin D1 expression in mid G1 phase.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7980579     DOI： 10.1006/bbrc.1994.2571

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro.

Authors:  E S Didier
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice.

Authors:  H J Bernsen; P F Rijken; H Peters; H Bakker; A J van der Kogel
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

4.  Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1.

Authors:  Y Zhang; E C Griffith; J Sage; T Jacks; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.

Authors:  H G Hotz; H A Reber; B Hotz; P C Sanghavi; T Yu; T Foitzik; H J Buhr; O J Hines
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

Review 6.  Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Authors:  William D Figg; Erwin A Kruger; Douglas K Price; Sonia Kim; William D Dahut
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

7.  Inhibition of tumor growth and microvascular angiogenesis by the potent angiogenesis inhibitor, TNP-470, in rats.

Authors:  M Niwano; S Arii; A Mori; S Ishigami; T Harada; M Mise; M Furutani; M Fujioka; M Imamura
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

8.  A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.

Authors:  Sang Joon Shin; Hei-Cheul Jeung; Joong Bae Ahn; Sun Young Rha; Jae Kyung Roh; Kyung Soo Park; Dal-Hyun Kim; Chin Kim; Hyun Cheol Chung
Journal:  Invest New Drugs       Date:  2009-07-08       Impact factor: 3.850

Review 9.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

10.  Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Authors:  Patrycja Koszałka; Ewa Szmit; Andrzej Myśliwski; Jacek Bigda
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.